Neuroendocrine neoplasms (NENs)
Neuroendocrine neoplasms (NENs) clinical guidelines
COSA has developed consensus guidelines for the management of neuroendocrine neoplasms (NENs). These guidelines aim to raise awareness of the increasing multidisciplinary management options, including supportive care, which may be appropriate for patients with this uncommon group of diseases.
NOTE: In the most recent nomenclature, neuroendocrine neoplasm (NEN) is the umbrella term. A well differentiated NEN is called a neuroendocrine tumour (NET), and a poorly differentiated NEN a neuroendocrine carcinoma (NEC). In these guidelines, NET may still be used as the overarching term when reporting the results of trials.
These draft guidelines are open for public consultation from 27 October 2022 to 30 November 2022.
We encourage you and your colleagues to review these draft guidelines. If you wish to make a comment, please email the responsible COSA Project Manager: email@example.com
When submitting a comment, please clearly identify the relevant chapter and section. Give as much detail as possible, for example:
- If you have identified any gaps or errors in the content, please suggest suitable text for inclusion.
- If you have comments on the language and/or terminology of the guidelines, please suggest replacement text.
- Feedback should be supported by scientific evidence.
At the end of the consultation period all feedback will be considered by the working group members, particularly the lead author/s of the section. Where appropriate, modifications will be made to the draft guidelines. The final version will be posted to a web-based platform in early 2023.